You are here

  • Home
  • Archive
  • Volume 10, Issue 10
  • Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy

Citation Tools

Article menu
Immunotherapy biomarkers
Original research
Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sun R, Lerousseau M, Briend-Diop J, et al
Radiomics to evaluate interlesion heterogeneity and to predict lesion response and patient outcomes using a validated signature of CD8 cells in advanced melanoma patients treated with anti-PD1 immunotherapy
Journal for ImmunoTherapy of Cancer 2022;10:e004867. doi: 10.1136/jitc-2022-004867